Home

James Paul Scopa

CIK 1356950 · last filed 2026-06-29

James Paul Scopa is a corporate insider who has filed 47 SEC Form 4 insider transactions across 6 companies since 2009. The most recent filing, for ALGS, was dated Jun 29, 2026. Across all open-market trades the lifetime net is +$1.9M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $38.2K across reported positions. 30 SEC filings were submitted jointly with VAUGHN M KAILIAN.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$38.2K

Companies

6

Total Filings

47

Lifetime Open-Market Net

$1.93M

Filer Profile

Reported Address
601 GATEWAY BOULEVARD
SUITE 350
SOUTH SAN FRANCISCO, CA 94080
Related Filers
VAUGHN M KAILIAN — 30 joint filings, latest 2016-09-29
John Vander Vort — 21 joint filings, latest 2013-06-06
Todd Foley — 20 joint filings, latest 2016-09-29
LUKE EVNIN — 19 joint filings, latest 2015-10-20
MPM BioVentures IV GP LLC — 18 joint filings, latest 2016-09-29
MPM BioVentures IV LLC — 18 joint filings, latest 2016-09-29
Steven St Peter — 18 joint filings, latest 2012-02-03
ANSBERT GADICKE — 17 joint filings, latest 2016-03-09
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
ALGS Director 7,323 $5.22 $38.2K $0 8 2026-06-29
Adverum Biotechnologies, Inc. (ADVM) Delisted Director 333 $4.36 $1.5K $297.7K 15 2025-12-10
DICE Director 0 $24.83 $0 -$188.5K 8 2023-08-09
Histogen Inc. (CNAT) Delisted Director 101,010 — — $1.82M 5 2018-06-25
TriVascular Technologies, Inc. (TRIV) Delisted Director 0 — — $0 2 2016-02-04
MEMY 10%+ Owner 0 $16.38 $0 $0 1 2009-01-05

Recent Filings

47 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-29 ALGS Grant (A) — $0 EDGAR
2025-12-10 Adverum Biotechnologies, Inc. (ADVM) Delisted Mixed −10,333 $0 EDGAR
2025-06-26 ALGS Grant (A) — $0 EDGAR
2025-06-20 Adverum Biotechnologies, Inc. (ADVM) Delisted Grant (A) — $0 EDGAR
2024-06-28 ALGS Grant (A) — $0 EDGAR
2024-06-20 Adverum Biotechnologies, Inc. (ADVM) Delisted Grant (A) — $0 EDGAR
2024-02-28 ALGS Mixed — $0 EDGAR
2024-02-09 Adverum Biotechnologies, Inc. (ADVM) Delisted Buy (P) +100,000 $135.0K EDGAR
2023-10-27 ALGS Grant (A) +183,083 $138.6K EDGAR
2023-08-09 DICE Disp (D) −40,921 $0 EDGAR
Showing 1–10 of 47
Page 1 of 5
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.